Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug composition containing irbesartan and hydrochlorothiazide

A technology of hydrochlorothiazide and its composition, which is applied in the field of pharmaceutical preparations, can solve the problems that there are no reports on the use of hydrochlorothiazide in small doses of irbesartan, and there are no literature reports on serum C-reactive protein of hydrochlorothiazide, so as to reduce cardiovascular morbidity and mortality, Good prognosis, increased effectiveness of prevention

Active Publication Date: 2014-04-30
NANJING CHIA TAI TIANQING PHARMA
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] To sum up, although there have been many reports on the combined application of irbesartan and hydrochlorothiazide to have a synergistic antihypertensive effect, all the reports are on the combined application of irbesartan and low-dose hydrochlorothiazide, and there is no report on the combination of irbesartan and hydrochlorothiazide. The use of low-dose irbesartan has been reported, and there is no literature report that hydrochlorothiazide combined with low-dose irbesartan can be used to reduce the risk of elevated serum C-reactive protein (CRP) in hypertensive patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composition containing irbesartan and hydrochlorothiazide
  • Drug composition containing irbesartan and hydrochlorothiazide
  • Drug composition containing irbesartan and hydrochlorothiazide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018]

[0019] Preparation process: first put hydrochlorothiazide and starch into a mortar, grind and mix evenly, then add sodium carboxymethyl starch and microcrystalline cellulose to mix evenly, finally add irbesartan and mix evenly, use 5% PVP in absolute ethanol solution Use it as a binder to prepare wet granules, dry at 40°C, granulate, add magnesium stearate, mix well, and compress into tablets.

Embodiment 2

[0021]

[0022]

[0023] Preparation Process:

[0024] Pass the irbesartan, hydrochlorothiazide, lactose, microcrystalline cellulose, and cross-linked polyvinylpyrrolidone in the prescription through a 100-mesh sieve, mix well, add 10% starch slurry to make granules, dry below 60°C, and use a 18-mesh sieve Whole grains, add the prescribed amount of magnesium stearate, mix well, and compress into tablets.

Embodiment 3

[0026]

[0027] Preparation Process:

[0028] Pass irbesartan, hydrochlorothiazide, starch, mannitol and L-HPC in the prescription through a 100-mesh sieve, mix well, add an appropriate amount of 10% starch slurry to granulate, dry below 50°C, granulate with a 18-mesh sieve, and add to the prescription Amount of magnesium stearate is mixed evenly, and tabletted is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composition containing irbesartan and hydrochlorothiazide. The drug composition is prepared into a tablet or a capsule by wet granulation of an active ingredient and a pharmaceutic adjuvant; the active ingredient comprises irbesartan and hydrochlorothiazide at a weight ratio of 1:(1.3-10); and the pharmaceutic adjuvant comprises a filler, a disintegrating agent, adhesive and a lubricant. With the adoption of the drug composition, impaired glucose tolerance is alleviated, the biological activity of insulin resistance is prevented, rising of a C-reactive protein level of a patient with hypertension can be prevented, the morbidity and mortality of and caused by various cardiovascular diseases in the future are reduced, and the drug composition has a very good improvement effect on the prognoses of the patient with the hypertension.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition containing irbesartan and hydrochlorothiazide. Background technique [0002] The occurrence of hypertension is caused by various factors such as hyperactivity of the sympathetic nervous system, renal water and sodium retention, and activation of the renin-angiotensin-aldosterone system (RAAS), and the existing antihypertensive drugs can only target a certain pathogenesis The mechanism works, and the antihypertensive effective rate of any antihypertensive drug is only 25%-50%. In order to effectively control blood pressure, 70% of hypertensive patients need to use antihypertensive drugs in combination. The 2007 European Society of Hypertension (ESH) / European Society of Cardiology (ESC) hypertension guidelines pointed out that the initial blood pressure is grade 2 or 3 hypertension, and patients with normal blood pressure but high or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/549A61K31/4184A61P9/12
Inventor 袁红波章晓骅
Owner NANJING CHIA TAI TIANQING PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products